Literature DB >> 8882950

Circulating clonotypic B cells in the biology of multiple myeloma: speculations on the origin of myeloma.

L M Pilarski1, A Masellis-Smith, A Szczepek, M J Mant, A R Belch.   

Abstract

The population of circulating B cells in myeloma patients includes an apparently large but variable subset with the IgH VDJ rearrangement diagnostic for the malignant clone of plasma cells in individual myeloma patients. Although the biological significance is at present unknown, it is likely that they include both malignant and non-malignant clonal relatives of the myeloma plasma cells. This article presents speculations on the significance of these cells in the origin of myeloma and the relationship between monoclonal gammopathy of undetermined significance (MGUS) and frank myeloma. MGUS appears to represent the establishment of clonal dominance probably by a chronically antigen-stimulated B cell clone. It seems likely that malignant transformation event(s) occurring in a clonal daughter cell give rise to myeloma. If correct, this implies that in a myeloma patient, non-malignant antigen-responsive B cells expressing the patient-specific IgH rearrangement coexist in the circulation and probably all lymphoid tissues, with their malignant antigen-independent relatives. However, the significance one attributes to the clonotypic B cells detected in the blood of myeloma patients depends in part on the view one takes of the progression from MGUS to myeloma. An alternative perspective is that MGUS represents a dormant state of malignancy held in check by controlled apoptosis, arrested cell cycling, and/or by immunoregulatory networks. Although lacking in experimental support, if this interpretation were correct, myeloma would occur when the regulatory mechanisms fail, allowing uncontrolled malignant cell renewal. This alternative view would imply that the majority of circulating clonotypic B cells might be malignant. Thus, an analysis of the biology of these clonotypic circulating B cells, with an emphasis on measures of malignancy, is likely to shed considerable light on the events underlying myeloma genesis, progression and spread.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882950     DOI: 10.3109/10428199609054775

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  11 in total

1.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

2.  Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with a high M-component.

Authors:  C Greco; F Ameglio; F Alvino; A Mosiello; A M Cianciulli; I Venturo; G Del Monte; M Giampaolo; A W Tong; G M Gandolfo
Journal:  Cell Prolif       Date:  1999-08       Impact factor: 6.831

3.  A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.

Authors:  Nagaaki Katoh; Tanya L Poshusta; Michelle K Manske; Angela Dispenzieri; Morie A Gertz; Roshini S Abraham; Marina Ramirez-Alvarado
Journal:  J Clin Immunol       Date:  2011-09-10       Impact factor: 8.317

4.  Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Authors:  Jana Jakubikova; Sophia Adamia; Maria Kost-Alimova; Steffen Klippel; David Cervi; John F Daley; Dana Cholujova; Sun-Young Kong; Merav Leiba; Simona Blotta; Melissa Ooi; Jake Delmore; Jacob Laubach; Paul G Richardson; Jan Sedlak; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2011-02-14       Impact factor: 22.113

Review 5.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 6.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

7.  Glycosylation of IgG B cell receptor (IgG BCR) in multiple myeloma: relationship between sialylation and the signal activity of IgG BCR.

Authors:  Vesna Ilić; Nadezda Milosević-Jovcić; Sonja Petrović; Dragana Marković; Gordana Stefanović; Tatjana Ristić
Journal:  Glycoconj J       Date:  2008-01-11       Impact factor: 2.916

8.  Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

Authors:  Linda M Pilarski; Eva Baigorri; Michael J Mant; Patrick M Pilarski; Penelope Adamson; Heddy Zola; Andrew R Belch
Journal:  Clin Med Oncol       Date:  2008-03-27

9.  Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.

Authors:  Martin Trepel; Victoria Martens; Christian Doll; Janina Rahlff; Barbara Gösch; Sonja Loges; Mascha Binder
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

10.  Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

Authors:  Katharina Blatt; Harald Herrmann; Gabriele Stefanzl; Wolfgang R Sperr; Peter Valent
Journal:  Oncotarget       Date:  2016-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.